PTCT Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$95.93median target· current $78.01 (+23.0%)14 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—Forward 56.82
EPS (TTM)$-2.540.0% YoY
Profit margin-22.6%HEALTHCARE
Market cap$6.52BMid cap
Valuation
- Forward P/E
- 56.82
- PEG ratio
- 0.81
- P/B
- 1743.27
- P/S (TTM)
- 7.88
- EV/EBITDA
- 6.88
Profitability & growth
- ROE (TTM)
- -7740.0%
- Operating margin
- 16.5%
- Revenue growth YoY
- -76.8%
- Dividend yield
- —
- Beta
- 0.53
Last earnings
May 7, 2026 · Estimate $-0.44 · Reported $-0.03
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About PTC Therapeutics Inc
Company profilePTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for patients with rare disorders. The company is headquartered in South Plainfield, New Jersey.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$6.52B
Shares outstanding$82.9M
52W high$90.87
52W low$43.17
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent